Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - linezolid, quantity: 200 mg - injection, solution - excipient ingredients: glucose monohydrate; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - choriogonadotropin alfa, quantity: 250 microgram - injection, solution - excipient ingredients: mannitol; water for injections; methionine; dibasic sodium phosphate dihydrate; poloxamer; phosphoric acid; sodium hydroxide; monobasic sodium phosphate monohydrate - ovidrel is indicated in the treatment of (i) women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (ivf): ovidrel is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth. (ii) anovulatory or oligo-ovulatory women: ovidrel is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - rocuronium bromide, quantity: 100 mg - injection, solution - excipient ingredients: glacial acetic acid; water for injections; sodium acetate trihydrate; sodium chloride - rocuronium bromide injection is indicated as an adjunct to general anaesthesia to facilitate endotracheal intubation during routine induction, to provide muscle relaxation and to facilitate mechanical ventilation in adults, children and infants over 1 month of age.,rocuronium is also indicated as an adjunct to general anaesthesia to facilitate endotracheal intubation during rapid sequence induction when suxamethonium is contraindicated, however, this has not been studied in infants and children.,rocuronium is also indicated as an adjunct in the intensive care unit (icu) to facilitate mechanical ventilation.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: methionine; acetic acid; mannitol; poloxamer; water for injections; benzyl alcohol; sodium hydroxide - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - corifollitropin alfa, quantity: 0.3 mg/ml - injection, solution - excipient ingredients: sodium citrate dihydrate; sucrose; hydrochloric acid; polysorbate 20; water for injections; sodium hydroxide; methionine - controlled ovarian stimulation (cos) for the development of multiple follicles and pregnancy in women undergoing in-vitro fertilisation techniques.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - arsenic trioxide, quantity: 10 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - for the induction of remission and consolidation in patients with acute promyelocytic leukaemia (apl) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.,for the induction of remission and consolidation in patients with previously untreated acute promyelocytic leukaemia (apl) in combination with all-trans retinoic acid (atra) and/or chemotherapy and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - midazolam, quantity: 5 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; sodium hydroxide; water for injections; nitrogen - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. iv for sedation in intensive care units; intermittent administration or continuous infusion. im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - midazolam, quantity: 5 mg/ml - injection, solution - excipient ingredients: nitrogen; hydrochloric acid; water for injections; sodium chloride; sodium hydroxide - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. iv for sedation in intensive care units; intermittent administration or continuous infusion. im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - midazolam, quantity: 1 mg/ml - injection, solution - excipient ingredients: nitrogen; hydrochloric acid; water for injections; sodium chloride; sodium hydroxide - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. iv for sedation in intensive care units; intermittent administration or continuous infusion. im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - midazolam, quantity: 5 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; sodium chloride; water for injections; nitrogen - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. iv for sedation in intensive care units; intermittent administration or continuous infusion. im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.